Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study

被引：0
|
作者：
Gatzemeier, U.
Ardizzoni, A.
Horwood, K.
van Meerbeeck, J.
Magyar, P.
Gottfried, M.
Arrieta, O.
Krzakowski, M.
Franke, F.
van Zandwijk, N.
机构：
[1] Hosp Grosshansdorf, Grosshansdorf, Germany
[2] Univ Hosp, Parma, Italy
[3] John Flynn Gold Coast Private Hosp, Tugun, Qld, Australia
[4] Univ Hosp, Ghent, Belgium
[5] Semmelweis Univ, Budapest, Hungary
[6] Meir Sapir Med Ctr, Kefar Sava, Israel
[7] Inst Nacl Cancerol, Mexico City, DF, Mexico
[8] Ctr Onkol Inst, Warsaw, Poland
[9] Hosp Caridade Ijui, Ijui, Brazil
[10] Antoni van Leeuwenhoe Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7645
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SAFETY AND EFFICACY OF ERLOTINIB IN NON-SMALL-CELL LUNG CANCER (NSCLC) IN ISRAEL: INTERIM ANALYSIS FROM THE TRUST STUDY
    Gottfried, M.
    Levitt, M.
    Wollner, M.
    Dudnik, J.
    Peylan-Ramu, N.
    Flex, D.
    Barak, F.
    Biran, H.
    Cyjon, A.
    Merimsky, O.
    ANNALS OF ONCOLOGY, 2008, 19 : 103 - 103
  • [2] Biomarker analysis from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC)
    Schneider, C.
    Roemer, K. Schott-von
    Guetz, S.
    Raack, B.
    Dierkesmann, R.
    Laack, E.
    Guschall, W.
    Schmittel, A.
    Gatzemeier, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis
    Franchina, T.
    Adamo, B.
    Caristi, N.
    Chiofalo, G.
    Toscano, G.
    Colonese, F.
    Denaro, N.
    Ricciardi, G. R.
    Russo, A.
    Adamo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [5] The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC)
    Groen, H.
    Arrieta, O. G.
    Riska, H.
    Horwood, K.
    Mali, P.
    Reck, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Reviewing the safety of erlotinib in non-small cell lung cancer
    Reck, Martin
    Mok, Tony
    Wolf, Juergen
    Heigener, David
    Wu, Yi-long
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (01) : 147 - 157
  • [7] Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)
    Ardizzoni, Andrea
    Razis, Evangelia
    Lichinitser, Mikhail
    Yilmaz, Ugur
    Grigorescu, Alexandru C.
    Morero, Jose Luis
    Skrickova, Jana
    Cervantes, Guadalupe
    Gottfried, Maya
    Van Meerbeeck, Jan
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S342 - S342
  • [8] GLOBAL EFFICACY AND SAFETY RESULTS FROM THE TRUST STUDY OF ERLOTINIB MONOTHERAPY IN > 7000 PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Reck, M.
    Mali, P.
    Arrieta, O.
    Gottfried, M.
    Van Meerbeeck, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 100 - 100
  • [9] Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Garon, E. B.
    Sadeghi, S.
    Kabbinavar, F. F.
    Reckamp, K. L.
    Marquez-Garban, D. C.
    Stabile, L. P.
    Goodglick, L.
    Dubinett, S. M.
    Siegfried, J. M.
    Pietras, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] LONG-TERM ERLOTINIB THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): INTERIM ANALYSIS OF BASELINE CHARACTERISTICS
    Chouaid, C.
    Gervais, R.
    Locher, C.
    Moro-Sibilot, D.
    Commenges, B.
    Chenoufi, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 446 - 446
12345